# AstraZeneca to sublicense its global rights to Movantik to RedHill Biopharma

- Link: https://www.directorstalkinterviews.com/astrazeneca-to-sublicense-its-global-rights-to-movantik-to-redhill-biopharma/412806391
- Published: 2020-02-25T07:16:07+00:00
- Author: Amilia Stone

**AstraZeneca** ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has today announced that it has agreed to sublicense its global rights to _Movantik_(
naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill).
_Movantik_ is a peripherally acting mu-opioid receptor antagonist indicated for 
the treatment of opioid-induced constipation.

> **Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said:**“
> This divestment supports our strategy to realise value from medicines in our portfolio
> that are mature or outside our current scope to enable reinvestment in our main
> therapy areas. _Movantik_ is an important established medicine and the divestment
> to RedHill will ensure its continued availability for patients.”

As part of the agreement, AstraZeneca will continue to manufacture and supply _Movantik_
to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialisation
agreement with Daiichi Sankyo, Inc. for _Movantik_ in the US, which will be transferred
to RedHill.

**Financial considerations**

RedHill will make an upfront payment of $52.5m to AstraZeneca on closing and a further
non-contingent payment of $15m in 2021. Income arising from the upfront payment,
offset by a charge for derecognition of the associated intangible asset, and the
future payment will be reported in AstraZeneca’s financial statements within Other
Operating Income & Expense. In 2019, _Movantik_ generated sales of $96m in the US.
The divestment is expected to complete in the first quarter of 2020, subject to 
customary closing conditions and regulatory clearances. Upon completion, the agreement
will not impact the Company’s financial guidance for 2020.

**Movantik**

_Movantik_ is a once-daily oral PAMORA approved by the US Food and Drug Administration
for the treatment of OIC in adult patients with chronic non-cancer pain. _Movantik_
was licensed from Nektar Therapeutics in 2009. It was developed using Nektar’s oral
small-molecule polymer conjugate technology. In 2016, AstraZeneca divested the rights
in Europe to ProStrakan Group (now KKI) and the rights in Canada and Israel to Knight
Therapeutics.

Share on:
